Educational programs Clinical updates Previous coverage ACG web site
AD109 Reduces OSA Severity in Phase 3 Trial of CPAP-Intolerant AdultsBySydney JenningsPublished: June 12th 2026 | Updated: June 12th 2026
Zasocitinib Tops Deucravacitinib for Skin Clearance in Phase 3 Psoriasis TrialBySydney JenningsJune 11th 2026
Women With Moderate-to-Severe OSA Report Greater Symptom Burden Than MenBySydney JenningsJune 10th 2026